PatientsVille.com Logo


Irbesartan Medical Research Studies

Up-to-date List of Irbesartan Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Irbesartan Medical Research Studies

Rank Status Study
1 Unknown  Irbesartan and Adhesion Molecules in AF
Condition: Persistent Atrial Fibrillation
Interventions: Drug: Irbesartan;   Drug: placebo
Outcome Measures: The primary target parameter is defined as reduction of systemic levels of oxidative stress markers and adhesion molecules (hsCRP, ICAM, VCAM, MCP-1, vWF, TGFβ1, TNF-α, Interleukin-6, 8isoProstaglandinF2α);   Number of cerebrovascular events;   Number of intermediate medical visits for cardiovascular reasons without hospitalization;   Number of hospitalization for cardiovascular reasons and GFR
2 Unknown  Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan
Conditions: Left Atrial Volume;   Hypertensive Heart Disease;   Antihypertensive Drugs;   Diastolic Function;   Renin Angiotensin System
Interventions: Drug: ramipril;   Drug: Irbesartan
Outcome Measures: left atrial volume;   diastolic function;   systolic and diastolic blood pressure
3 Recruiting The Oxford Marfan Trial
Condition: Marfan Syndrome
Interventions: Drug: Irbesartan 150-300mg capsules daily for 6 months;   Drug: Doxycycline 100-200mg capsules daily for 6 months;   Drug: Doxycycline placebo capsules daily for 6 months;   Drug: Irbesartan placebo capsules daily for 6 months
Outcome Measures: Change (i.e. difference between first and last study visits) in aortic distensibility in the ascending aorta between allocation arms measured using CMR;   1. Change in aortic distensibility in the proximal and distal descending aorta between allocation arms measured using CMR;   2. Change in aortic dimensions in the proximal and distal descending aorta;   3. Change in mean and peak axial and mean and peak circumferential aortic wall shear stress between allocation arms estimated by CMR using a 4D flow sequence;   4. Change in peripheral (brachial) blood pressure between allocation arms measured using a calibrated, validated automated sphygmomanometer;   5. Change in central blood pressure, and augmentation index between allocation arms measured by applanation tonometry and by oscillometric sphygmomanometry;   6. Change in left ventricular volumes, mass and systolic function between allocation arms to placebo measured by CMR;   7. Change in aortic pulse wave velocity between allocation arms measured by CMR;   8. Change in carotid-femoral pulse wave velocity between allocation arms compared to placebo measured by applanation tonometry;   9. Change in TGF-β level, or other biomarker, between allocation arms compared to placebo;   10. Tolerability and safety of Irbesartan and doxycycline, assessed by incidence of adverse reactions and change in health status score, using the SF-36 questionnaire;   11. Document the frequency of aortic dissection, death from cardiovascular causes, or need for aortic root or valve surgery (if any) in each allocation arm
4 Not yet recruiting Angiotensin II Antagonist in Severe Sepsis
Condition: Severe Sepsis
Intervention: Drug: Irbesartan
Outcome Measures: mortality;   Incidence of altered organ function in sepsis patients measured by SOFA score (Sequential Organ Failure Assessment score)
5 Unknown  Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension and Permanent Pacemakers
Conditions: Atrial Fibrillation;   Hypertension
Intervention: Drug: Irbesartan
Outcome Measures: Time to recurrent AHRE ( 220/min for > 2 minutes);   - Frequency of AHRE’s (> 220/min for > 2 minutes) Evaluated at randomization, month 1 and 6.;   - Development of sustained AF (>30 minutes), documented;   by ECG, holter, rhythm strip or pacemaker electrograms;   - Electrical Remodeling (AERP,SNRT,paced/sensed p-wave;   duration). Evaluated at randomization, months 1 and 6.;   - Markers of Inflammation (Plasma CRP,TNF-alpha, D-Dimer,;   IL-6, Pro-collagen-III products, BNP,MPO,hsP). Blood collection at randomization and month 6.;   - Structural Remodeling (left atrial volume, left;   ventricular mass, left ventricular diastolic function. Evaluated at randomization and month 6.
6 Unknown  Combined Antihypertensive Therapy and Sexual Dysfunction
Conditions: Hypertension;   Sexual Dysfunction
Interventions: Drug: Felodipine add Irbesartan;   Drug: Felodipine add Metoprolol
Outcome Measures: Female Sexual Function Index (FSFI);   International Index of Erectile Function(IIEF);   Change of Systolic Blood Pressure in 2 Weeks;   Change of Systolic Blood Pressure in 4 Weeks;   Change of Systolic Blood Pressure in 8 Weeks;   Change of Systolic Blood Pressure in 12 Weeks;   Change of Systolic Blood Pressure in 24 Weeks;   Change of Systolic Blood Pressure in 48 Weeks;   Change of Diastolic Blood Pressure in 2 Weeks;   Change of Diastolic Blood Pressure in 4 Weeks;   Change of Diastolic Blood Pressure in 8 Weeks;   Change of Diastolic Blood Pressure in 12 Weeks;   Change of Diastolic Blood Pressure in 24 Weeks;   Change of Diastolic Blood Pressure in 48 Weeks;   Serum Estradiol in 24 Weeks;   Serum Estradiol in 48 Weeks;   Serum Testosterone in 24 Weeks;   Serum Testosterone in 48 Weeks;   Serum MDA in 24 Weeks;   Serum MDA in 48 Weeks;   Serum 8-OHdG in 24 Weeks;   Serum 8-OHdG in 48 Weeks;   Serum HNE in 24 Weeks;   Serum HNE in 48 Weeks
7 Unknown  Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat)Clinical Study
Conditions: Hypertension;   Metabolic Syndrome
Outcome Measure:
8 Recruiting Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Condition: Focal Segmental Glomerulosclerosis
Interventions: Drug: RE-021 (Sparsentan);   Drug: Irbesartan
Outcome Measure: Evaluate change in urine protein/creatinine (Up/C).
9 Not yet recruiting Clinical Trial in Patients With Hypertension and Left Ventricular Dysfunction
Conditions: Hypertension;   Cardiac Arrhythmias;   Diabetes Mellitus;   Renal Insufficiency;   Sleep Apnea
Outcome Measures: Blood pressure measurement;   Quality of Life questionnaire rating
10 Recruiting Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
Condition: IgA Nephropathy
Interventions: Drug: Irbesartan;   Drug: methylprednisolone (MP) or prednisone (pred);   Drug: mycophenolate mofetil (MMF)
Outcome Measures: Remission of proteinuria (complete or partial);   Deterioration of renal function (evidenced by a 50% rise from baseline serum creatinine (SCr) levels, or a 25% decline from baseline eGFR levels, or onset of end-stage renal disease or dialysis treatment, or kidney transplantation)
11 Unknown  The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension
Conditions: Abdominal Obesity;   Hypertension
Interventions: Drug: Moxonidine;   Drug: Irbesartan
Outcome Measures: Microneurography (nerve recording);   Blood test
12 Recruiting Sevelamer in Proteinuric CKD
Condition: Chronic Kidney Disease
Interventions: Drug: Sevelamer;   Drug: Ramipril and Irbesartan
Outcome Measures: 24-h urinary protein excretion;   Office blood pressure;   Glomerular Filtration Rate
13 Recruiting Preeclampsia: A Marker for Future Cardiovascular Risk in Women
Conditions: Preeclampsia;   Pregnancy Induced Hypertension
Intervention: Drug: Irbesartan
Outcome Measures: Vascular function;   Hormonal measurements
14 Recruiting Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Cardiovascular Risk Assessment
Conditions: Essential Hypertension;   Cardiovascular Disease;   Stroke;   Chronic Kidney Disease
Interventions: Drug: Any antihypertensive medication alone or in combination;   Device: Ambulatory blood pressure monitoring
Outcome Measures: To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular and renal risk assessment.;   To evaluate the influence of circadian time of treatment in BP control of hypertensive patients.;   To evaluate the prevalence of an altered (non-dipper) BP profile in patients with resistant hypertension as a function of the circadian time of treatment.;   To evaluate the influence of diabetes and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.;   To evaluate the influence of age and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.;   To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of white-coat hypertension.;   To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of masked hypertension.;   To evaluate, for all previous objectives, potential differences between men and women.;   To evaluate the impact of changes in ambulatory BP in cardiovascular, cerebrovascular and renal risk assessment.
15 Recruiting RAS Blockade at Bedtime Versus on Awakening for Aldosterone Breakthrough
Condition: Chronic Kidney Disease
Intervention: Other: Randomization that determine the time of treatment
Outcome Measures: Serum aldosterone levels at one year;   Serum aldosterone/renin ratio;   Significant aldosterone breakthrough Significant aldosterone breakthrough
16 Recruiting Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol
Condition: Marfan Syndrome
Interventions: Drug: Aliskiren;   Drug: Atenolol
Outcome Measures: Central aortic PWV(pulsed wave velocity);   Central aortic distensibility by MRI at week 24
17 Recruiting Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics
Condition: Hypertension
Intervention: Other: Sevoflurane/oxygen/air/nitrous oxide
Outcome Measures: Systemic Vascular Resistance Index (SVRI);   Heart Rate;   Systolic Blood Pressure;   Diastolic Blood Pressure;   Central Venous Pressure;   Cardiac Output (CO);   Cardiac Index (CI);   Stroke Volume Varriation;   Systemic Vascular Resistance
18 Recruiting Renal Denervation in Diabetic Nephropathy
Conditions: Diabetic Nephropathy;   Persistent Proteinuria With Type II Diabetes
Interventions: Procedure: Percutaneous renal denervation and TMNS;   Drug: Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
Outcome Measures: proteinuria/creatininuria ratio;   Number of patients with a decrease of the PU/CrU >50% ratio;   Evaluation of the slope of decay of the PU/CrU;   eGFR is estimated by the MDRD formula, and is expressed in mL/min/1.73m². The direct GFR will be assessed by measuring the 51Cr-EDTA plasmatic clearance;   Outcome of the GFR assessed by 51Cr-EDTA clearance;   Decrease of the blood pressure assessed on ABPM;   Anti-hypertensive regimen score;   Evaluation of the renal arterial anatomy;   Evaluation of safety and tolerance of renal denervation in diabetic patients with overt proteinuria;   Evaluate the outcome of biological parameters;   Evaluate the diabetic neuropathy/dysautonomy;   Evaluate the outcome of specific kidney injury markers

These studies may lead to new treatments and are adding insight into Irbesartan etiology and treatment.

A major focus of Irbesartan research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Irbesartan